Skip to main content

Table 1 Patient characteristics

From: Correlation between blood magnesium and calcium concentration in patients treated with an anti-EGFR antibody

n = 22   Mean ± S.D. Median Range
Age (year)   66.09 ± 7.78 65 51–80
Sex
 Male 17    
 Female 5
Body Height (cm)   162.84 ± 8.35 163.35 149.00–175.30
Body Weight (kg)   58.14 ± 9.11 56.55 40.00–74.00
PS
 0 14    
 1 6
 2< 2
Type of cancer
 Colon 13    
 Rectal 7
 Cecum 2
EGFR-targeting antibodies
 Cetuximab 14    
 Panitumumab 8
No metastatic sites
 One 7    
 Two 8
 Three or more 7
Involved sites 6    
 Lung 13    
 Liver 14
 Lymph nodes 3
 Bone 0
 Peritoneal 7
Median treatment cycle    9.30 1.00–23.00
Median treatment duration, weeks    9.00 2.00–46.00
Combination of Magnesium oxide formulation
 Yes 11    
 No 11
Combination regimen
 FOLFIRI base 15    
 FOLFOX base 2
 CPT-11 2
 Monotherapy 3
Serum Magnesium (mg/dL)   2.13 ± 0.22 2.00 1.80–2.60
Serum Calcium (mg/dL)   9.96 ± 0.33 9.85 9.50–10.50
Laboratory data
 Neu (/mm3)   3716.8 ± 1459.1 3475.0 1380.0–6880.0
 WBC (/mm3)   5936.3 ± 1685.9 5450.0 3200.0–10100.0
 PLT (/mm3)   207,091 ± 5651 205,500 111,000–330,000
 Hb (g/dl)   11.67 ± 1.73 11.55 7.80–14.4
 sCre (mg/dl)   0.73 ± 0.31 0.64 0.51–1.88
 AST (IU/l)   20.40 ± 4.44 21.00 12.00–28.00
 ALT (IU/l)   15.40 ± 7.08 13.50 5.00–30.00
  1. Patients treated with anti-EGFR antibodies = 43; serum Ca level was measured for all patients